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Ne
ofOBJECTIVES This study sought to develop a novel parsimonious score for predicting technical success of chronic total
occlusion (CTO) percutaneous coronary intervention (PCI) performed using the hybrid approach.
BACKGROUND Predicting technical success of CTO PCI can facilitate clinical decision making and procedural planning.
METHODS We analyzed clinical and angiographic parameters from 781 CTO PCIs included in PROGRESS CTO
(Prospective Global Registry for the Study of Chronic Total Occlusion Intervention) using a derivation and validation
cohort (2:1 sampling ratio). Variables with strong association with technical success in multivariable analysis were
assigned 1 point, and a 4-point score was developed from summing all points. The PROGRESS CTO score was subse-
quently compared with the J-CTO (Multicenter Chronic Total Occlusion Registry in Japan) score in the validation cohort.
RESULTS Technical success was 92.9%. On multivariable analysis, factors associated with technical success included
proximal cap ambiguity (beta coefﬁcient [b] ¼ 0.88), moderate/severe tortuosity (b ¼ 1.18), circumﬂex artery CTO
(b ¼ 0.99), and absence of “interventional” collaterals (b ¼ 0.88). The resulting score demonstrated good calibration and
discriminatory capacity in the derivation (Hosmer-Lemeshow chi-square ¼ 2.633; p ¼ 0.268, and receiver-operator char-
acteristic [ROC] area ¼ 0.778) and validation (Hosmer-Lemeshow chi-square ¼ 5.333; p ¼ 0.070, and ROC area ¼ 0.720)
subset. In the validation cohort, the PROGRESS CTO and J-CTO scores performed similarly in predicting technical success
(ROC area 0.720 vs. 0.746, area under the curve difference ¼ 0.026, 95% conﬁdence interval ¼ 0.093 to 0.144).
CONCLUSIONS The PROGRESS CTO score is a novel useful tool for estimating technical success in CTO PCI performed
using the hybrid approach. (J Am Coll Cardiol Intv 2016;9:1–9) © 2016 by the American College of Cardiology Foundation.m the *VA North Texas Health Care System and University of Texas Southwestern Medical Center, Dallas, Texas; yPiedmont
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AUC = area under the curve
CABG = coronary artery bypass
graft surgery
CTO = chronic total occlusion
LCX = left circumﬂex
PCI = percutaneous coronary
intervention
ROC = receiver-operator
characteristic
TIMI = Thrombolysis In
Myocardial Infarction
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2C hronic total occlusion (CTO) percu-taneous coronary intervention (PCI)can be challenging, with variable
success rates (1–3). Identifying clinical and
angiographic characteristics associated with
procedural failure could lead to improvement
of patient selection and possibly an increase
of overall success of CTO PCI. In the J-CTO
(Multicenter Chronic Total Occlusion Registry
in Japan) study, 5 variables (occlusion
length $20 mm, blunt stump, CTO calciﬁca-
tion, CTO tortuosity, and prior failed attempt)
were combined to create a 5-point score,
which could be used to predict successfulguidewire crossing within the ﬁrst 30 min (4). The
J-CTO score demonstrated a dose-response relation-
ship with the study’s endpoint and had good discrimi-
natory ability. However, it was not associated with
CTO PCI success rates in a Canadian single-operator
CTO PCI registry that used the hybrid approach (5).SEE PAGE 10The hybrid approach differs from the crossing
approach used in the J-CTO registry, as it encourages
rapid switch between various crossing strategies aim-
ing for efﬁcient, safe, and effective CTO PCI crossing
(6). Moreover, prior failure is a subjective factor
that is heavily dependent on the expertise of the
CTO operator who attempted the procedure. In theis, Minnesota; zzCollege of Health Innovation, University
cientiﬁc, Natick, Massachusetts.Research reported in this publ
Translational Sciences of the National Institutes of Health under a
ity of the authors and does not necessarily represent the ofﬁcial vi
rom Boston Scientiﬁc and Medtronic Cardiovascular; and has re
nd Medtronic Cardiovascular. Dr. Yeh has received a Career Dev
, and Blood Institute; has served as a consultant for Abbott Vascu
sory board of Abbott Vascular; and receives salary support fromHa
ant to Boston Scientiﬁc, Siemens, andMerck; has received nonﬁna
search grants from the National Institutes of Health (HL-R01-1082
akers Bureau for Abbott Vascular, Boston Scientiﬁc, and Medtro
r. Wyman has received honoraria/consulting/speaking fees from
s received consulting fees from Terumo, Asahi Intecc, and Bosto
pport from Abbott Laboratories. Dr. Lombardi has equity with Br
ntiﬁc, Abiomed, and Abbott Vascular. Dr. Grantham has received
ntiﬁc, Abbott Vascular, and Asahi Intecc; has received research
ndMedtronic; is a member of the Boston Scientiﬁc Executive Phys
d is on the CTO advisory board for Abbott Vascular. Dr. Moses has
r. Rangan has received research grants from Infraredx and The Sp
ureau for Abbott Vascular, Boston Scientiﬁc, and Medtronic; and h
nic. Dr. Garcia has received consulting fees from Medtronic and
r. Banerjee has received research grants from Gilead and the M
rom Covidien, Medtronic, and Merck; has ownership in MDCARE G
oth spouse); and has intellectual property in HygeiaTel. Dr. Brila
cular, Asahi, Boston Scientiﬁc, Elsevier, Somahlution, St. JudeMed
ntiﬁc and Infraredx; and his spouse is an employee of Medtroni
s relevant to the contents of this paper to disclose.
received May 27, 2015; revised manuscript received August 10, 2present study, we attempted to develop a novel, parsi-
monious, and easy-to-use score to allow estimation of
the likelihood of technical success among CTO PCI
procedures performed using the hybrid approach.METHODS
PATIENT POPULATION. We reviewed the clinical and
angiographic records of consecutive patientswhowere
included in PROGRESS CTO (Prospective Global Reg-
istry for the Study of Chronic Total Occlusion Inter-
vention) (NCT02061436) (7–12) between January 2012
and January 2015 at 7 U.S. centers with signiﬁcant
expertise in CTO PCI: Appleton Cardiology, Appleton,
Wisconsin; Massachusetts General Hospital, Boston,
Massachusetts; Piedmont Heart Institute, Atlanta,
Georgia; St. Joseph Medical Center, Bellingham
Washington; St. Luke’s Health System’s Mid-America
Heart Institute, Kansas City, Missouri; Torrance Me-
morial Medical Center, Torrance, California; and
VA North Texas Healthcare System, Dallas, Texas.
Procedures were prospectively and retrospectively
entered into the database. No speciﬁc baseline clinical
or angiographic criteria were used to justify or exclude
study enrollment. The study was approved by the
institutional review board of each center.
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TABLE 1 Baseline Demographic and Angiographic Characteristics in the
Derivation Set (n ¼ 521 Lesions)
Technical Success
(n ¼ 482)
Technical Failure
(n ¼ 39) p Value
Age, yrs 65  10 66  11 0.57
Male 85 89 0.63
BMI, kg/m2 31  6 30  5 0.69
EF 50  14 49  15 0.78
Dyslipidemia 94 100 0.24
Hypertension 89 92 0.79
Current smoking 33 44 0.19
Prior MI 40 57 0.06
CHF 28 25 0.69
Prior PCI 66 84 0.023
Prior CABG 34 46 0.13
Dialysis 2 0 0.99
PVD 16 14 0.99
COPD 12 8 0.53
Target vessel
RCA 60 53 0.001
LAD 23 8
LCX 17 39
Occlusion length, mm 37  25 42  23 0.27
Vessel diameter, mm 2.8  0.5 2.7  0.4 0.12
Proximal cap ambiguity 26 52 0.006
Side branch at proximal cap 42 58 0.12
Good distal opaciﬁcation 50 38 0.24
Distal cap at bifurcation 29 38 0.34
Good distal landing zone 59 54 0.68
Collateral ﬁlling
Ipsilateral 16 23
Contralateral 54 62 0.29
Both 28 12
None 2 4
No interventional collaterals 35 58 0.034
Moderate or severe calciﬁcation* 56 59 0.67
Moderate or severe tortuosity† 31 56 0.005
In-stent restenosis 13 18 0.32
Prior attempt 16 24 0.22
Values are mean  SD or %. *Deﬁned as any evident calciﬁcation within the CTO segment,
excluding spot calciﬁcation. †Deﬁned as 2 bends >70 or 1 bend >90 .
BMI ¼ body mass index; CABG ¼ coronary artery bypass grafting; CHF ¼ chronic heart failure;
CTO ¼ chronic total occlusion; CVD ¼ cerebrovascular disease; EF ¼ ejection fraction; LAD ¼ left
anterior descending artery; LCX ¼ left circumﬂex artery; MI ¼ myocardial infarction; PCI ¼
percutaneous coronary intervention; PVD ¼ peripheral vascular disease; RCA ¼ right coronary
artery.
TABLE 2 Multivariable Analysis in the Derivation Subset (n ¼ 521)
OR for Technical
Failure (95% CI) Chi-Square p Value b Coefﬁcient Points
No interventional collaterals 2.40 (0.92–6.55) 3.16 0.076 0.88 1
Proximal cap ambiguity 3.86 (1.49–10.43) 7.62 0.006 1.35 1
Moderate or severe tortuosity 3.25 (1.22–9.28) 5.63 0.021 1.18 1
LCX CTO 2.69 (1.00–7.14) 4.00 0.046 0.99 1
Prior PCI 1.64 (0.54–6.13) 0.69 0.391 0.25 0
CI ¼ conﬁdence interval; OR ¼ odds ratio; other abbreviations as in Table 1.
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3duration. Estimation of the occlusion duration was on
the basis of ﬁrst onset of anginal symptoms, prior
history of myocardial infarction in the target vessel
territory, or comparison with a prior angiogram.
“Interventional collaterals” were deﬁned as collat-
erals that were amenable to crossing with a guidewire
and a microcatheter according to the judgment of the
operator. Technical success of CTO PCI was deﬁned as
successful CTO revascularization with achievement
of <30% residual diameter stenosis within the treated
segment and restoration of antegrade TIMI ﬂow
grade 3. The J-CTO score was calculated as described
by Morino et al. (4).
SCORE DERIVATION. We separately performed ana-
lyses in population subsets that were used for deriva-
tion (2/3 random sampling rate, 521 lesions) and
validation (1/3 random sampling rate, 260 lesions).
Univariable analysis was performed to identify clinical
and angiographic variables associated with technical
failure. We performed an all-inclusive analysis of the
clinical and angiographic characteristics that are
available in the PROGRESS CTO registry. Variables
with a strong (p < 0.05) association then entered a
multivariable model. The multivariable analysis was
used to identify independent predictors of technical
failure. The effect size was quantiﬁed by the beta (b)
coefﬁcient and the strength of association was de-
monstrated with the chi-square statistic and p value.
Independent predictors were selected on the basis of
strength of association (p < 0.10) in context with clin-
ical evidence from prior published scientiﬁc data. The
b coefﬁcients of the independent predictors were then
used to estimate the number of points that would be
assigned to a speciﬁc factor. Subsequently, all points
accrued were summed to create the scoring index.
STATISTICAL ANALYSIS. Continuous data were
summarized as mean  SD (normally distributed data)
or median and interquartile range (IQR) (non-
normally distributed data) and compared using the
t test or Wilcoxon rank-sum test, as appropriate.
Categorical data were presented as frequencies or
percentages and compared using chi-square or Fisher
exact test, as appropriate. The calibration of the score
was assessed with the Hosmer-Lemeshow chi-square
statistic and the lack of ﬁt tests. The discriminatory
capacity was evaluated with the receiver-operator
characteristic (ROC) curves and with the calculated
area under the curve (AUC) (13). The PROGRESS CTO
score was validated with comparison of the ROC
curves in the derivation and validation cohorts.
Subsequently, the score and the score elements
were separately re-evaluated in 1,000 bootstrapped
samples of the study population. Bootstrapped
FIGURE 1 Summary of the PROGRESS CTO Score
CTO ¼ chronic total occlusion; PROGRESS CTO ¼ Prospective Global Registry for the Study
of Chronic Total Occlusion Intervention.
TABLE 3 Clinical and Angiographic Characteristics in the
Derivation and Validation Subsets
Derivation Set
(n ¼ 521)
Validation Set
(n ¼ 260) p Value
Age, yrs 65  10 66  10 0.23
Male 85 89 0.12
BMI, kg/m2 31  6 30  6 0.39
EF 50  14 51  13 0.24
Dyslipidemia 95 95 0.91
Hypertension 89 90 0.62
Current smoking 34 30 0.18
Prior MI 42 38 0.42
CHF 28 24 0.33
Prior PCI 67 65 0.62
Prior CABG 35 36 0.71
Dialysis 2 2 0.86
PVD 16 18 0.47
COPD 11 12 0.93
Target vessel
RCA 59 61 0.93
LAD 22 21
LCX 19 18
Occlusion length, mm 37  25 34  25 0.15
Vessel diameter, mm 2.8  0.5 2.8  0.5 0.73
Proximal cap ambiguity 30 28 0.96
Side branch at proximal cap 43 42 0.76
Good distal opaciﬁcation 50 52 0.63
Distal cap at bifurcation 30 34 0.39
Good distal landing zone 59 56 0.56
Collateral ﬁlling
Ipsilateral 17 16
Contralateral 55 58 0.88
Both 27 24
None 2 2
No interventional collaterals 37 36 0.78
Moderate or severe calciﬁcation 56 61 0.25
Moderate or severe tortuosity 33 33 0.88
In-stent restenosis 13 10 0.35
Prior attempt 17 18 0.71
Values are mean  SD or %.
Abbreviations as in Table 1.
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4b coefﬁcients with their respective conﬁdence in-
tervals (CIs) were reported. Finally, comparison with
the J-CTO score was performed in the validation
cohort. Statistical analyses were performed with JMP
version 11.0 (SAS Institute, Cary, North Carolina)
and SPSS version 22.0 (IBM Corporation, Armonk,
New York). A p value <0.05 was considered statisti-
cally signiﬁcant.
RESULTS
PATIENT POPULATION AND PROCEDURAL OUTCOMES.
The study cohort consisted of 781 CTO PCI procedures
performed in 762 patients. Mean age was 65  10
years, and most of the patients were men (87%) with
frequent history of prior coronary artery bypass graft
surgery (CABG) (35%), prior myocardial infarction
(41%), and prior PCI (66%). The most common CTO
PCI target vessel was the right coronary artery (59%),
followed by the left anterior descending artery (21%)and the left circumﬂex artery (LCX) (19%). Technical
success was achieved in 726 procedures (92.9%). The
mean J-CTO score among successful versus failed
CTO PCIs was 2.5  1.2 versus 3.3  1.0, respectively
(p < 0.001). Median procedure and ﬂuoroscopy time
was 114 min (IQR: 79 to 166.5 min) and 42 min (IQR:
25 to 69 min), respectively. Median patient air kerma
dose and contrast volume were 3.5 Gray (IQR: 2.0
to 5.7 Gray) and 250 ml (IQR: 190 to 350 ml),
respectively.
SCORE DERIVATION AND VALIDATION. The deriva-
tion subset included 521 CTO PCIs, of which technical
success was achieved in 482 (92.5%). As compared
FIGURE 2 Comparison of the Performance of PROGRESS CTO
Score in the Derivation and Validation Sets
Derivation set area under the curve ¼ 0.778; validation set area
under the curve ¼ 0.720. PROGRESS CTO ¼ Prospective Global
Registry for the Study of Chronic Total Occlusion Intervention.
FIGURE 3 Sensitivity and Speciﬁcity of the PROGRESS CTO and J-CTO Scores in the
Derivation and Validation Cohorts
(A) Progress CTO score; (B) J-CTO (Multicenter Chronic Total Occlusion Registry in Japan)
score. Abbreviations as in Figure 1.
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5with successful procedures, failed procedures were
more likely to be performed among patients with
prior PCI (84% vs. 66%; p < 0.023), proximal cap
ambiguity (52% vs. 26%; p ¼ 0.006), lack of inter-
ventional collaterals (58% vs. 35%; p ¼ 0.034), mod-
erate or severe tortuosity (56% vs. 31%; p ¼ 0.005),
and LCX as the target vessel (39% vs. 17%; p < 0.001)
(Table 1). These variables were included in the
multivariable analysis, and results are demonstrated
on Table 2. Four of the 5 parameters (proximal cap
ambiguity, lack of interventional collaterals, LCX PCI,
and moderate/severe tortuosity) remained indepen-
dently associated with technical failure. As the
magnitude of their effect was similar (b coefﬁcient
range ¼ 0.88 to 1.35), 1 point was assigned to each of
the variables selected, creating the PROGRESS CTO
score (Figure 1).
Clinical and angiographic characteristics were
equally distributed between the derivation and vali-
dation subsets (Table 3). The PROGRESS CTO score’s
AUCs in the derivation and validation cohorts were
0.778 and 0.720, respectively (AUC difference ¼
0.058, 95% CI: 0.125 to 0.241) (Figure 2). Hosmer-
Lemeshow chi-square values in derivation and
validation cohorts were chi-square ¼ 2.633 (p ¼ 0.268)
and chi-square ¼ 5.333 (p ¼ 0.070), respectively. The
score was successful in predicting technical success
with stepwise alterations in sensitivity and speciﬁcity
for each PROGRESS CTO point (Figure 3A). Procedural
time demonstrated only a moderate increase relativeto higher scores (Figure 4). Bootstrapped b co-
efﬁcients for the score elements were as follows: lack
of interventional collaterals: 0.836 (95% CI: 0.021 to
1.608; p ¼ 0.032); proximal cap ambiguity: 1.451
(95% CI: 0.693 to 2.380; p ¼ 0.001); tortuosity: 0.659
(95% CI: 0.097 to 1.493; p ¼ 0.080); LCX interven-
tion: 0.955 (95% CI: 0.094 to 1.754; p ¼ 0.011).
Collinearity diagnostics, including tolerance and
FIGURE 4 Box Plot of Total Procedure Time in Each PROGRESS CTO Score Stratum in
the Derivation and Validation Sets
PROGRESS CTO ¼ Prospective Global Registry for the Study of Chronic Total Occlusion
Intervention.
FIGURE 5 Receiver-Operator Characteristic Curves of the
PROGRESS CTO and J-CTO Scores in the Validation Dataset
PROGRESS CTO score (area under the curve ¼ 0.720) and the
J-CTO score (area under the curve ¼ 0.746). Abbreviations as in
Figures 1 and 3.
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6variance inﬂation factor statistics, indicated no
evidence of multicollinearity. The PROGRESS CTO
score’s relationship with technical failure was also
conﬁrmed with bootstrapping: b coefﬁcient: 0.931
(95% CI: 0.597 to 1.342; p ¼ 0.001).
COMPARISON WITH J-CTO SCORE TO PREDICT
TECHNICAL SUCCESS. We compared the PROGRESS
CTO score with the J-CTO score in the validation
subset (Figure 5). The AUC was 0.720 for the
PROGRESS CTO score and 0.746 for the J-CTO score
(AUC difference: 0.026; 95% CI: 0.093 to 0.144).
Similar predicting accuracy was noted for each stra-
tum of both scores (Figures 3A and 3B). However, the
J-CTO score demonstrated better discriminatory
ability in the lower scores (J-CTO sensitivity 93.3% to
100% and speciﬁcity 5.2% to 22.0% vs. PROGRESS
CTO sensitivity 80.0% to 90.0% and speciﬁcity 30.6%
to 68.3% for scores 0 to 1) in the validation dataset.
DISCUSSION
Our study shows that the PROGRESS CTO score can be
an effective tool in predicting the likelihood of CTO
PCI technical success and guide clinical decision-
making. The PROGRESS CTO score had similar pre-
dictive ability as the J-CTO score, but is simpler with
4 rather than 5 factors and does not include the priorCTO PCI failure, which can be unreliable given
different skillsets at different CTO PCI centers and
among various operators. Additionally, unlike the
J-CTO score that was developed to predict procedural
efﬁciency (i.e., guidewire crossing within 30 min), the
PROGRESS CTO score was speciﬁcally developed to
predict technical failure (12), which is a more clini-
cally important endpoint.
The “hybrid” CTO crossing algorithm is commonly
used to guide selection of CTO PCI crossing strategy
in the U.S. and increasingly around the world (6). The
“hybrid” algorithm assesses 4 key angiographic CTO
characteristics (proximal cap ambiguity, quality of
the vessel distal to the occlusion, lesion length, and
presence of adequate collateral vessels) to determine
the subsequent crossing strategy (antegrade wiring,
dissection and re-entry, and retrograde). Three of
those 4 characteristics were included in the
PROGRESS CTO score, namely proximal cap ambigu-
ity, tortuosity (surrogate for distal vessel quality),
and presence of interventional collaterals. Lesion
length was not independently associated with pro-
cedural success, likely because novel crossing tech-
niques (such as antegrade or retrograde dissection
and re-entry) may allow for rapid and safe crossing of
long occlusion segments.
Several angiographic and clinical parameters have
been associated with CTO PCI success, such as prior
CABG (14,15), calciﬁcation, lesion length, and tortuos-
ity (16). Success is also heavily dependent on operator
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7experience and expertise (17). Experienced operators
can currently achieve >85% success rates, even in
complex patient subgroups, such as patients with
prior CABG and in-stent restenosis (8,11). All operators
contributing cases to the PROGRESS CTO registry were
experienced, high-volume CTO PCI operators who
performed procedures using a standardized CTO
crossing approach.
The retrograde approach to CTO PCI (18,19) is an
important complement to the antegrade crossing
approaches, especially in cases where the proximal
cap is poorly visualized or in challenging lesions
where antegrade crossing has failed (6,20). Absence
of “interventional” collaterals, that is, collaterals
suitable for the retrograde approach, deprives the
operator of an alternative crossing strategy and
contributes to the likelihood of technical failure.
In centers with signiﬁcant experience, the retro-
grade approach can be performed with high efﬁ-
cacy rates and a favorable efﬁciency and safety
proﬁle (21–26).
The J-CTO score’s primary outcome measure was
CTO PCI efﬁciency (guidewire crossing time <30 min);
the PROGRESS score used ﬁnal angiographic success
as the primary endpoint. Although the discriminatory
capacity of the PROGRESS and the J-CTO scores was
similar, the PROGRESS CTO score has 2 key advan-
tages: 1) it includes key variables of the widely uti-
lized hybrid algorithm that are not included in the
J-CTO score (proximal cap ambiguity and presence of
interventional collaterals; as well as circumﬂex CTO
target vessel); and 2) it does not include a parameter
of questionable value (prior CTO PCI failure, as the
success or failure of the prior procedure heavily de-
pends on the experience of the operator who per-
formed that procedure). These differences may reﬂect
recent advances in CTO PCI, such as expanded use of
antegrade dissection/re-entry (27–29) and the retro-
grade approach (24,26,30,31) that may allow more
efﬁcient and successful crossing of complex and long
CTOs. The lower success rates for circumﬂex CTO
target vessel is likely related to increased tortuosity
of this vessel and the less frequent presence of
“interventional” collaterals (9).
STUDY LIMITATIONS. PROGRESS CTO is an observa-
tional registry without adjudication of clinical events
by a clinical events committee. Quantitative coronary
angiographic analysis was not performed, and there-
fore, assessment of angiographic characteristics was
susceptible to operator-related bias. In particular,
characterization of a collateral vessel as “interven-
tional collateral” is subjective and depends heavily on
operator experience. Even among the best CTOoperators, only approximately 70% to 80%of collateral
vessels attempted are successfully crossed with a
guidewire and a microcatheter (32). Moreover, if an
operator is unable to wire a collateral, he or she might
be more likely to code it as a “noninterventional”
collateral. No long-term follow-up of the CTO patients
was available. All procedures were performed by
seasoned operators with signiﬁcant CTO PCI training
limiting extrapolation of the study results to less
experienced centers and operators. The low failure
rate (7.1%) in the derivation cohortmay limit the power
of univariable and multivariable analyses, due to
paucity of observations in the failure group. However,
it is expected that in case of a higher failure rate, the
increase in model diagnostic accuracy would also in-
crease statistical signiﬁcance of the score components.
Validation of the PROGRESS CTO score in an external
dataset would further strengthen our ﬁndings. Our
analysis did not account for correlation in the limited
number of patients (n ¼ 17, 2%) who had PCI of 2 CTO
lesions during the same procedure. However, reitera-
tion of the analysis after excluding these lesions did
not signiﬁcantly change the PROGRESS CTO score
derivation. Finally, guidewire crossing time was not
available, and total procedure time was used as a
measure of procedural efﬁciency, which is related to
multiple factors in addition to guidewire crossing time.
CONCLUSIONS
Evaluation of 4 baseline angiographic characteristics
(proximal cap ambiguity, absence of retrograde collat-
erals, moderate or severe tortuosity, and LCX CTO)
can be used to determine the likelihood of technical
success with CTO PCI. The PROGRESS CTO score is a
simple tool that can be used in clinical practice to predict
CTO PCI success and guide clinical decision-making.
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PERSPECTIVES
WHAT IS KNOWN? Currently there are limited
tools for predicting the likelihood of success of
CTO PCI.
WHAT IS NEW? We developed the PROGRESS CTO
score for predicting technical success of CTO PCI. The
score includes 4 variables: proximal cap ambiguity,
moderate/severe tortuosity, circumﬂex artery CTO, and
absence of “interventional” collaterals. The PROGRESS
CTO score demonstrated good calibration and discrimi-
natory capacity and performed similar to the J-CTO score
in predicting technical success.
WHAT IS NEXT? Clinical application and external valida-
tion of the PROGRESS-CTO score are needed to further
reﬁne its clinical utility.
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